226 related articles for article (PubMed ID: 19776716)
41. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Samuel D; Bizollon T; Feray C; Roche B; Ahmed SN; Lemonnier C; Cohard M; Reynes M; Chevallier M; Ducerf C; Baulieux J; Geffner M; Albrecht JK; Bismuth H; Trepo C
Gastroenterology; 2003 Mar; 124(3):642-50. PubMed ID: 12612903
[TBL] [Abstract][Full Text] [Related]
42. [APRICOT Study evaluated. Surprisingly high virologic response in HIV-HCV coinfection].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():74-5. PubMed ID: 15373058
[No Abstract] [Full Text] [Related]
43. [A case of Bell's palsy associated with peginterferon Alfa-2a and ribavirin therapy for chronic hepatitis C virus infection].
Lee MY; Cho H; Kim YM; Lee JS
Korean J Hepatol; 2006 Sep; 12(3):444-8. PubMed ID: 16998297
[TBL] [Abstract][Full Text] [Related]
44. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
Liu CH; Liang CC; Liu CJ; Tsai HB; Hung PH; Hsu SJ; Chen SI; Lin JW; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
Gut; 2009 Feb; 58(2):314-6. PubMed ID: 19136527
[No Abstract] [Full Text] [Related]
45. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
Neumann U; Puhl G; Bahra M; Berg T; Langrehr JM; Neuhaus R; Neuhaus P
Transplantation; 2006 Jul; 82(1):43-7. PubMed ID: 16861940
[TBL] [Abstract][Full Text] [Related]
46. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
47. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
Mukherjee S
Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
[TBL] [Abstract][Full Text] [Related]
48. Autoimmune fulminant hepatic failure in chronic hepatitis C during Peg-interferon-alpha 2b plus ribavirin treatment showing histological heterogeneity.
Yasui S; Fujiwara K; Yokosuka O
Dig Liver Dis; 2011 Aug; 43(8):666-7. PubMed ID: 21435960
[No Abstract] [Full Text] [Related]
49. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
[TBL] [Abstract][Full Text] [Related]
50. Vitiligo improvement in a hepatitis C patient after treatment with PEG-interferon alpha-2a and ribavirin: a case report.
Taffaro M; Pyrsopoulos N; Cedron H; Cacayorin E; Weppler D; Moon J; Nishida S; Levi D; Kato T; Selvaggi G; Tzakis A; Schiff E
Dig Dis Sci; 2007 Dec; 52(12):3435-7. PubMed ID: 17431776
[No Abstract] [Full Text] [Related]
51. [A case of sudden-onset hearing loss in a patient treated with peginterferon alpha-2b and ribavirin for chronic hepatitis C].
Shin MK; Kim TH; Ju K; Ha CY; Min HJ; Jung WT; Lee OJ
Korean J Hepatol; 2009 Sep; 15(3):370-4. PubMed ID: 19783887
[TBL] [Abstract][Full Text] [Related]
52. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
53. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
[TBL] [Abstract][Full Text] [Related]
54. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Papastergiou V; Skorda L; Lisgos P; Karatapanis S
Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
[No Abstract] [Full Text] [Related]
55. Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C.
Rotman Y; Katz L; Cohen M; Cohen-Ezra O; Manhaim V; Braun M; Ben-Ari Z; Tur-Kaspa R
J Viral Hepat; 2009 May; 16(5):340-5. PubMed ID: 19220735
[TBL] [Abstract][Full Text] [Related]
56. [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].
Bruch-Gerharz D; Reifenberger J
Hautarzt; 2006 Apr; 57(4):317-35. PubMed ID: 16523277
[No Abstract] [Full Text] [Related]
57. Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis.
Mederacke I; Witte T; Wedemeyer H; Meyer-Olson D
Ann Rheum Dis; 2011 Jul; 70(7):1343-4. PubMed ID: 21131645
[No Abstract] [Full Text] [Related]
58. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
[No Abstract] [Full Text] [Related]
59. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
[No Abstract] [Full Text] [Related]
60. Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.
Puoti C; Lanzetta G; Scotti E
J Gastrointestin Liver Dis; 2016 Sep; 25(3):408-9. PubMed ID: 27689211
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
